The Role of Tumor-associated Macrophages in Colorectal Liver Metastases

Colorectal Cancer Clinical Trial

Official title:

Search for the Clinical Significance of Tumor-associated Macrophages in Patients With Colorectal Liver Metastases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03888638
• Other study ID #: TAMs in CLM
• Status: Completed
• Start date: January 1, 2015
• Est. completion date: March 1, 2019

Study information

• Verified date: March 2019
• Source: Humanitas Clinical and Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colorectal cancer is a major cause of mortality worldwide. Most patients develop colorectal liver metastases (CLM), and for such patients hepatectomy combined with chemotherapy may be curative. Nevertheless, in the era of precision medicine there is a critical need of prognostic markers to cope with the heterogeneity of CLM patients. Tumor-associated macrophages (TAMs) pave the way to tissue invasion and intravasation providing a nurturing microenvironment formetastases. The quantification of immune landscape of tumors has provided novel prognostic indicators of cancer progression, and the quantification of TAMs might explain the heterogeneity of CLM patients. Here, we will investigate the development of a new diagnostic tool based on TAMs with the aim to define the causative role of TAMs in CLM patients. This will open new clinical scenarios both for the diagnosis, therapy and prognosis, leading to the refinement of the therapeutic output in a personalized medicine perspective.

Description:

Some preliminary data produced by the research team from Humanitas Clinical and Research Center in Milan (ITALY) have shown that TAMs in CLM are heterogeneous and that their diversity can be distinguished based on their morphology and functionality. Therefore, TAMs may represent an additional tool in the definition of the biology and prognosis of CLM patients. This preliminary finding provides us with the rationale to undertake a prospective study on a large series of CLM patients surgically resected by our unit aimed at validating the promisingcorrelation between different TAMs phenotypes and patients prognosis. The characterization of the diversity of TAMs in CLM will be refined using state of the art technology, including multi-parametric flow cytometry, single cell RNA sequencing (scRNA-seq) transcriptional profiling, metabolomic, and proteomic analyses. The expected findings will allow us to develop a new diagnostic tool based on TAMs features, which will open the way to new criteria for patient stratification and for the design of new targeted therapies in a personalized medicine perspective.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: March 1, 2019
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with colorectal liver metastases undergoing hepatectomy

• Full clinical, surgical, pathological and follow-up data

• Availability of tissues for the analysis

Exclusion Criteria:

• Missing (any) data

• Combination of radiofrequency or microwave ablation plus surgery

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Liver Metastases
• Colorectal Neoplasms
• Immunotherapy
• Liver Metastases
• Liver Neoplasms
• Neoplasm Metastasis
• Neoplasms, Second Primary

Intervention

Procedure:
• Hepatectomy
Removal of a part of the liver because of tumor

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Humanitas Clinical and Research Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	Analysis of survival after hepatic resection for colorectal liver metastases according with the tumor-associated macrophages characteristics	From date of surgery until the date of first documented progression or date of death from any cause, which ever came first assessed up to 72 months]